Last updated on July 2019

An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers


Brief description of study

A study to evaluate the safety of Nivolumab given in combination with Ipilimumab in patients with advanced cancers. The initial group will enroll patients with newly diagnosed Stage 4 or non-small cell lung cancer that has come back.

Clinical Study Identifier: NCT02869789

Find a site near you

Start Over

Local Institution

Gent, Belgium
1.06miles
  Connect »